回复@interbin: Harrison is more bearish on ImmunoGen’s pipeline. He puts a $0 value on the proprietary pipeline and $2 per share value on the partnered pipeline. The most promising drug could only add $1.5 of annual revenue per share, according to the research note.//@interbin:回复@外向孤独患者1984:@医药邦 大神来点评了